| Active substance | efgartigimod alfa |
| Holder | argenx |
| Status | Running |
| Indication | Acetylcholine receptor antibody negative patients with gMG who participated in and exited study ARGX-113-2002 OR who were treated via early access |
| Public documents | Approbation |
| Information for the patient | |
| informed consent | |
| Last update | 29/10/2024 |